The latest results from the CITF-funded ENCORE study, led by Dr. Kate Zinszer (Université de Montréal), looking at seroprevalence among children and adolescents in Montreal, found that 58% of young children and teens had infection-acquired antibodies between May and September 2022.
In a preprint, not yet peer-reviewed, CITF-funded researcher Dr. Pascal Lavoie (University of British Columbia) and colleagues found that children in British Columbia have been more vulnerable to respiratory syncytial virus (RSV) following a lull while protective measures were in place at the height of the COVID-19 pandemic.
In a preprint, not yet peer-reviewed, CITF-funded researchers Drs. Kate Zinszer (University of Montreal) and Caroline Quach (University of Montreal, Research Centre of the Sainte-Justine University Hospital) identified a variety of factors that contributed to an increased risk of seropositivity and seroconversion in children and adolescents.
In a pre-print, not yet peer reviewed, Dr. Meghan Azad (University of Manitoba) and her team reported on the study design and cohort profile for research examining the prevalence and predictors of SARS-CoV-2 infection and transmission, as well as the predictors of the health and psychosocial impacts from the COVID-19 pandemic among Canadian children and their families.
The latest, preliminary, non-peer reviewed results from the EnCORE study (Round Three) show an increasing number of Montreal youth, aged 2 to 17, acquired antibodies due to a SARS-CoV-2 infection between October 2020 and December 2021.
Where an average of 1,450 cases of respiratory syncytial virus (RSV) are reported each year in British Columbia, only five cases were reported in the province in 2020-2021 due largely to drastically reduced interactions while provincial lockdowns were in effect.
A CITF-funded study by researcher Dr. Kate Zinszer from the Université de Montréal and colleagues found that SARS-CoV-2 antibodies due to infection in children aged 2 to 17 years in Montreal increased over time, from 3.2% in October-November 2020 to 8.4% in March-April 2021.
In a letter published in Gut, Dr. Kevan Jacobson, Dr. Pascal Lavoie and collaborators from the University of British Columbia report modestly lower antibody levels in adolescents, aged 12 to 17 years, with inflammatory bowel disease (IBD) who are on the anti-TNF-a anti-inflammatory therapy infliximab in combination with other immunosuppressive drugs or given as monotherapy, after a first dose of Pfizer-BioNTech’s Comirnaty vaccine.
Drs. Pascal Lavoie and Louise Mâsse from the University of British Columbia and their team have released new findings from their CITF-funded study of SARS-CoV-2 transmission in Vancouver schools.
As part of their CITF-funded COVID-19 cohort study, Dr. Kate Zinszer and Dr. Caroline Quach from the Université de Montréal, along with colleagues, examined whether parents from certain socioeconomic backgrounds or racialized groups were more – or less – inclined to have their child or adolescent vaccinated.